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UPDATE Open Access
Statistical analysis plan for the PlAtelet
Transfusion in Cerebral Haemorrhage
(PATCH) trial: a multicentre randomised
controlled trial
M. Irem Baharoglu1, Rustam Al-Shahi Salman2, Charlotte Cordonnier3, Rob J. de Haan4 and Yvo B. W. E. M. Roos1*
Abstract
Background: Use of antiplatelet therapy shortly before stroke due to spontaneous primary intracerebral haemorrhage
(ICH) is associated with higher case fatality in comparison to ICH without prior antithrombotic drug use. The PlAtelet
Transfusion in Cerebral Haemorrhage (PATCH) trial aimed to assess the effect of platelet transfusion in patients
presenting with ICH while using antiplatelet therapy. The main hypothesis of PATCH was that platelet transfusion
would reduce death or dependence by reducing ICH growth.
Methods/Design: PATCH was a multicentre prospective, randomised, open, blinded endpoint (PROBE) parallel group
trial, conducted at 60 hospitals in The Netherlands, Scotland and France. Forty-one sites enrolled 190 patients with
spontaneous supratentorial ICH aged ≥18 years, who had used antiplatelet therapy for ≥7 days preceding ICH, if
Glasgow Coma Scale was ≥8. Participants were randomised (1:1, with a secure web-based system using permuted
blocks, stratified by study centre and type of antiplatelet therapy pre-ICH) to receive either platelet transfusion within
6 hours of symptom onset and 90 minutes of diagnostic brain imaging, or standard care without platelet transfusion.
The primary outcome was modified Rankin Scale (mRS) score assessed blind to treatment allocation at 3 months after
ICH. Planned secondary outcomes included ICH growth on brain imaging performed approximately 24 hours after
randomisation, survival at 3 months, disability at 3 months scored using the Amsterdam Medical Centre linear disability
score, heterogeneity of treatment effect on mRS and ICH growth according to presence of the computed tomography
angiography spot sign, causes of poor outcome, and cost-effectiveness. Safety outcomes were transfusion reactions,
thromboembolic complications, and serious adverse events occurring during hospitalisation. This statistical analysis
plan was written without knowledge of the unblinded data.
Trial registration: The trial was registered with the Netherlands Trial Register on 29 April 2008 (NTR1303).
Keywords: Stroke, Intracerebral haemorrhage, Platelet transfusion, Haemostatic drugs, Randomised controlled trial,
Statistical analysis plan
Update
Background
Haemorrhagic stroke causes 11 % of all new strokes in
high-income countries and 22 % in low-middle income
countries [1], yet the 2013 Global Burden of Disease
study estimated that haemorrhagic stroke accounted for
half of all stroke deaths and approximately 47 million
(42 %) of the disability-adjusted life-years lost due to
stroke [2]. Spontaneous (non-traumatic) intracerebral
haemorrhage (ICH) caused by cerebral small vessel dis-
eases (so-called ‘primary’ ICH) accounts for two-thirds of
haemorrhagic stroke [3]. ICH causes >2 million strokes
per year, and more than one quarter of patients with inci-
dent ICH in high-income countries are already taking
antiplatelet drug therapy at the time of ICH [4–6].* Correspondence: y.b.roos@amc.uva.nl1Department of Neurology, Academic Medical Centre, H2-222, PO Box
226601100 DD Amsterdam, The Netherlands
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In a systematic review and meta-analysis of 25 cohort
studies, antiplatelet therapy use at the time of ICH was
associated with an increase in the risk of death (multi-
variable adjusted odds ratio [OR] 1.27, 95 % confidence
interval [CI] 1.10 to 1.47) in comparison to patients with
ICH not taking antithrombotic drugs [7]. In observa-
tional analyses, pre-ICH antiplatelet therapy use and re-
duced platelet activity have been associated with early
ICH volume growth [8, 9], which is one of the most
important determinants of poor outcome after ICH [10].
Consequently, for people taking antiplatelet therapy
shortly before ICH, restoration of platelet function may
improve haemostasis, reduce ICH growth, and thereby
improve outcome. Observational studies have varied in
their support for this hypothesis [11–16], but rando-
mised controlled trials have not tested the effects of
platelet transfusion on clinical outcomes for people
with acute ICH associated with the use of antiplatelet
therapy [16, 17].
Therefore, we designed the PlAtelet Transfusion in
Cerebral Haemorrhage (PATCH) randomised controlled
trial to test the hypothesis that for people with acute
ICH associated with the use of antiplatelet therapy,
platelet transfusion compared to standard care without
platelet transfusion reduces death or dependence. One
other similar trial is ongoing (NCT00699621). The
PATCH trial has been registered (Netherlands Trial
Register NTR1303), its protocol has been published [18],
and we now describe the final statistical analysis plan,
which was written and submitted without knowledge of
the outcome data.
Objectives
Primary objective
The primary aim of the PATCH trial was to investigate
whether platelet transfusion reduced poor outcome at 3
months after ICH affecting patients who were using an-
tiplatelet therapy at the time of ICH. The poor outcome
of death or dependence was defined in the protocol as a
modified Rankin Scale (mRS) score of 4 to 6 [18].
Secondary objectives
The secondary aims of the PATCH trial were to investi-
gate whether platelet transfusion: was safe; decreased
ICH growth; improved survival at 3 months; reduced
poor outcome across the full ordinal scoring range of
the mRS at 3 months; reduced poor outcome defined as
mRS scores 3 to 6 at 3 months; and reduced disability at
3 months scored using the Amsterdam Medical Centre
linear disability score (ALDS). We aimed to perform a
sub-study to determine whether the presence of the ‘spot
sign’ on computed tomography angiography (CTA) at
baseline modified the effect of platelet transfusion on
the primary outcome and ICH growth [19]. We also
intended to describe the causes of poor outcome and
cost-effectiveness of the intervention [18].
Design
PATCH was a multicentre prospective, randomised, open,
blinded endpoint (PROBE) parallel group trial conducted
at 60 hospitals in The Netherlands, Scotland, and France.
Between 4 February 2009 and 8 October 2015, 41 sites
enrolled 190 patients with spontaneous supratentorial
ICH aged ≥18 years, who had used antiplatelet therapy for
≥7 days preceding ICH, if Glasgow Coma Scale was ≥8.
Participants were randomised in a 1:1 ratio to receive ei-
ther platelet transfusion within 6 hours of symptom onset
and 90 minutes of diagnostic brain imaging, or standard
care without platelet transfusion. Allocation concealment
was ensured by a secure web-based system using per-
muted blocks, stratified by study centre and type of anti-
platelet therapy pre-ICH (cyclooxygenase inhibitor only,
adenosine diphosphate (ADP) receptor inhibitor only,
cyclooxygenase inhibitor in combination with an adeno-
sine reuptake inhibitor, or cyclooxygenase inhibitor in
combination with ADP receptor inhibitor). Patients and
investigators were not blinded to the allocated treatment
group, but the primary outcome was assessed blind to
treatment allocation at 3 months after ICH.
Inclusion criteria
1. Age ≥ 18 years
2. Non-traumatic, supratentorial ICH confirmed by
brain imaging
3. Glasgow Coma Scale score 8–15
4. Antiplatelet therapy with a cyclooxygenase inhibitor
(aspirin or carbasalate calcium), or ADP receptor
inhibitor (clopidogrel), or an adenosine reuptake
inhibitor (dipyridamole) used for at least the 7 days
preceding ICH
5. Treatment can be initiated within 6 hours of symptom
onset and within 90 minutes of brain imaging
6. Pre-stroke modified Rankin Scale score of 0 (no
symptoms) or 1 (no significant disability despite
symptoms; able to carry out all usual duties and
activities)
Exclusion criteria
1. Haematoma on brain imaging suggestive of epidural
or subdural haematoma, or an underlying aneurysm
or arteriovenous malformation
2. Planned surgical evacuation of haematoma within 24
hours after admission
3. Presence of intraventricular blood more than
sedimentation in the posterior horns of the lateral
ventricles
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4. Previous adverse reaction to platelet transfusion
5. Known use of vitamin K antagonists [unless
international normalised ratio (INR) ≤1.3]
6. Known thrombocytopenia < 100 x 109/L
7. History of coagulopathy
8. Mental incapacity, by legal criteria, before stroke
9. Death appears imminent
10. No written informed consent
Intervention
Patients were assigned in a 1:1 ratio to receive either
standard care + platelet transfusion or standard care
alone. Platelet transfusion had to be initiated within 6
hours after onset of ICH symptoms and within 90 mi-
nutes of brain imaging. Platelets were supplied by na-
tional or regional blood supply organisations, issued by
the hospital transfusion laboratory, and transfusion was
carried out according to local transfusion protocols.
Patients using aspirin/carbasalate calcium or adenosine
reuptake inhibitor without an ADP receptor inhibitor
were given either a single buffycoat-derived leucocyte-
depleted platelet adult dose equivalent unit or a single
leucocyte-depleted platelet unit. Patients using ADP re-
ceptor inhibitors, either alone or in combination with
other antiplatelet therapy, were given two units.
Standard care was not defined, but was given ac-
cording to European [20] and national guidelines of
the time [21, 22].
Data collection
Investigators were asked to record patient characteristics
and demographics before randomisation, which only re-
quired the patient’s age and pre-ICH antiplatelet therapy
to be specified. Brain computed tomography (CT) or
magnetic resonance imaging (MRI) ± angiography was
performed in routine clinical practice at hospital admis-
sion. Repeat brain imaging was performed as a trial pro-
cedure and was intended to be the same modality as
baseline scan, done at 24 ± 3 hours after randomisation.
Diagnostic and 24-hour brain imaging studies were
obtained in DICOM format from trial sites, and analysed
centrally in Amsterdam. Investigators collected informa-
tion about the occurrence of serious adverse events/re-
actions during hospital admission and the date and
destination of discharge. Neurologists or research nurses
who were trained and blinded to treatment allocation
collected follow-up data at 3 months after randomisa-
tion by use of either structured telephone interview or
face-to-face interview. Data were collected centrally in
the different participating countries. Good clinical
practice (GCP)-compliant internet-based remote data
capture (Oracle Clinical, Redwood Shores, CA, USA)
was used for entering, managing, and validating the
data from the sites.
Primary outcome
 Poor outcome (death or dependence), defined as a
mRS score of 4 to 6, at 3 months after
randomisation.
Secondary outcomes
 Safety of platelet transfusion (see Safety below)
 ICH growth, defined as the absolute difference in
intraparenchymal ICH volume (mL) between
brain imaging at baseline and repeat imaging after
24 ± 3 hours, assessed by automated planimetric
software, checked by two independent radiologists
for accuracy
 Survival at 3 months
 The full ordinal score range of mRS at 3 months
 Poor outcome defined as mRS 3–6 at 3 months
 Disability at 3 months scored using the Amsterdam
Medical Centre linear disability score (ALDS)
 Presence of the ‘spot sign’ on CTA at baseline and
whether this modified the effect of platelet transfusion
on the primary outcome and ICH growth
 Causes of poor outcome
 Cost-effectiveness of platelet transfusion
Safety
Investigators recorded all adverse events during hospitalisa-
tion and reported any adverse event that was considered to
be a serious adverse event (SAE) if it resulted in death, was
life threatening (at the time of the event), required pro-
longation of hospitalisation, or resulted in persistent or
significant disability or incapacity, or any other important
medical event. Safety outcomes were classified as:
 Complications of ICH (ICH growth, brain oedema,
brain herniation, intraventricular extension,
hydrocephalus)
 Thromboembolic complications (cerebral infarction,
myocardial infarction, systemic embolism,
pulmonary embolism)
 Transfusion reactions (non-haemolytic, anaphylactic,
transfusion-related acute lung injury, post-transfusion
purpura, graft-versus-host disease, transfusion-
transmitted bacterial infection)
 Other (infection – urinary tract or pulmonary – and
epileptic seizures)
Statistical methods specified in the protocol
Sample size calculation
We estimated that at least 70 % of participants would
have poor outcome (mRS 4 to 6) [18]. We aimed for an
absolute reduction in the risk of this poor outcome by
20 % to 50 %. A two-group chi-squared test with a 0.05
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two-sided significance level would have 80 % power to
detect a 20 % absolute risk difference between a stand-
ard care group of 95 patients in which 70 % experi-
enced poor outcome and a platelet transfusion group of
95 patients in which 50 % experienced poor outcome at
3 months (OR = 0.43). With this sample size, a two-
sided 95 % CI for the difference between the propor-
tions would extend 13.6 % from the observed difference
in proportions.
Proposed analyses
Baseline characteristics will be summarized using simple
descriptive statistics. The main analysis of the PATCH
trial was going to consist of a single comparison between
the trial treatment groups of the primary outcome after
3 months (dichotomised mRS score 0–3 vs. 4–6). The
analysis will be based on the intention-to-treat principle.
The effect size will be expressed in a relative risk esti-
mates and absolute risk reduction. Additionally the pri-
mary outcome will be analysed using multivariable
logistic regression, adjusting (if necessary) for clinically
relevant baseline imbalances and treatment characteris-
tics. The effect size will be expressed in an adjusted OR.
With regard to the range of secondary outcome parame-
ters we will use simple 2 × 2 tables, two-group t tests,
Mann-Whitney U tests, and multivariable linear and
logistic regression models, when appropriate. With re-
spect to the primary outcome predefined subgroup ana-
lyses will be performed: (a) pre-ICH antiplatelet therapy,
(b) treatment within 2.5 hours versus 2.5–6 hours after
symptom onset. In all analyses, statistical uncertainty
will be quantified with 95 % CIs.
Interim analyses and safety reporting
The Data Safety Monitoring Board (DSMB – see
Appendix) consisted of three independent trial experts
(one statistician, one neurologist, and one expert in vas-
cular medicine) to monitor safety and perform an ana-
lysis of unblinded effectiveness data at one time point
after inclusion of 100 patients in the trial. At the time of
inclusion of the 100th patient, SAEs needed to be re-
corded and reported to the trial coordinating centre, and
the DSMB needed to be reconstituted (Appendix), by
which time 160 patients had been included in the trial
and an interim analysis could be performed on the first
154 patients for whom both outcome and SAE data were
available. The DSMB were provided with a report pre-
pared by an independent statistician that included base-
line variables [gender, age, antiplatelet therapy, and
National Institutes of Health Stroke Scale (NIHSS)
score], SAEs, the primary outcome, and a distribution of
the mRS in each of the arms of the trial unblinded to
the treatment group. The DSMB was instructed in a
charter to look at safety (deaths and the number of SAEs
in both groups) and efficacy (primary outcome, dichoto-
mised 0–3 vs. 4–6, using a Haybittle-Peto stopping rule
with a p value set at 0.001 [23]). The DSMB assessed the
unblinded data in a closed session, independent of the
investigators, in October 2015. The DSMB had not been
provided with a pre-specified threshold for futility.
Additionally the DSMB was asked to advise the
executive committee on possible continuation of the
trial beyond its pre-specified sample size if analyses
showed a possible signal of efficacy. By the time the
DSMB gave its final advice to the executive committee,
the trial had just reached its pre-specified sample size
of 190 patients. The verdict of the DSMB was that their
advice was without consequence for the study and to
not include more patients beyond the pre-specified
sample size. There was a separate DSMB in France that
performed ongoing safety monitoring for patients in-
cluded in France (see Appendix).
Statistical analysis plan
Overall principles
The data analysis will start after the 3-month follow-up
data of the last included patient has been obtained, and
after the clinical trial module of the study database has
been cleaned and locked.
The analyses will be done by a co-investigator (MIB) su-
pervised by the principal investigator (YBWEMR) and an
independent epidemiologist/statistician of the Amsterdam
Medical Centre Clinical Research Unit. The statistical pro-
gramming and analysis to produce all summary tables and
figures will use the statistical package IBM SPSS statistics
version 22 (IBM Corp., Armonk. NY, USA).
In general, variables will be summarised using sim-
ple descriptive statistics such as means with standard
deviation for continuous symmetric variables, me-
dians and interquartile ranges for continuous skewed
variables, and frequencies with percentages for cat-
egorical variables.
All analyses will be done according to the intention-
to-treat principle, by analysing patients in the groups to
which they were allocated by randomisation. The ana-
lyses will first be performed blind to treatment alloca-
tion, to allow for checking of the data and the proposed
summaries/analyses. After the investigation and correc-
tion of any isolated or systematic data errors, treatment
allocation will be unmasked. The primary outcome will
be analysed in the pre-specified subgroups below, irre-
spective of the presence of statistical significance in the
overall analysis. Safety outcomes will be additionally ana-
lysed in the as-treated (not per protocol) population.
Overall level of statistical significance
According to Haybittle-Peto’s stopping rule, no adjust-
ment of the p value will be used for the final analysis
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[23]. A two-sided p value < 0.05 will be considered
statistically significant. Statistical uncertainty will be
expressed in a two-sided 95 % CI.
Handling of missing data
Missing baseline and outcome data will not be imputed.
We will state which data are missing and calculate fre-
quencies using the total number of patients with avail-
able data. When a patient is lost to follow-up or has
withdrawn consent, we will use all available data up until
withdrawal of consent or loss to follow-up. A specific
section in the paper will report on missing data.
Definition of populations for analysis
The unit of analysis will be the patient.
Intention-to-treat population
All randomised patients will be analysed in the treat-
ment group to which they were originally allocated irre-
spective of non-adherence or deviations from protocol.
Occasionally, investigators randomised the same pa-
tient twice in the web-based randomisation system
because they were not aware of the treatment alloca-
tion from the first randomisation; in these cases, the
treatment allocation of the second randomisation was
used in practice, and will be used in the final ana-
lyses, and the first unused randomisation record was
removed from the trial database.
As-treated population
Patients will be analysed in groups according to treat-
ment received irrespective of allocated treatment at ran-
domisation, thus creating a group that did not receive
platelet transfusion (control) and a group that received
any platelet transfusion (intervention). The patients will
still be included in the as-treated analysis if there was a
protocol violation (e.g. not receiving treatment within
the described time frame, not receiving the correct num-
ber of units of platelets, or not meeting inclusion or ex-
clusion criteria).
List of analyses
Recruitment and retention
The trial profile and inclusion will be shown in a
Consolidated Standards of Reporting Trials (CONSORT)
flow diagram, including the total number of randomised
patients and then showing per treatment group the
numbers receiving allocated treatment, withdrawing
consent, and lost to follow up.
Baseline characteristics
The baseline characteristics of all participants in each
treatment group will be outlined in a table, but no
formal statistical testing will be performed. The table
will describe the following variables: age, sex, vascular
co-morbidities, history of coagulopathy, type of anti-
platelet therapy (as used for stratification), use of a sta-
tin, Glasgow Coma Scale score, NIHSS score, platelet
count, ICH location and volume on baseline imaging,
presence/extent of intraventricular blood on baseline im-
aging, and the ICH score [24].
Protocol deviations and violations
All substantial protocol violations will be listed.
Adherence to allocated treatment
Adherence will be reported descriptively.
Primary outcome
We have chosen to quantify the effect of platelet transfu-
sion on the primary outcome of the mRS at 3 months
with the common OR and 95 % CI from an ordinal lo-
gistic regression analysis of the shift of all categories of
the mRS [25], rather than using the pre-specified fixed
dichotomous approach. We have explained our rationale
for this below. First a “crude” OR with 95 % CI will be
calculated after which multivariable regression analysis
will be used to adjust for the following:
▪ Type of antiplatelet therapy used (stratification
variable: cyclooxygenase inhibitor only vs. ADP
receptor inhibitor only vs. cyclooxygenase inhibitor in
combination with an adenosine reuptake inhibitor vs.
cyclooxygenase inhibitor in combination with ADP
receptor inhibitor).
▪ ICH severity, quantified by the ICH score [24]
▪ Any large, chance imbalances at baseline between
intervention and control groups in covariates that
might have a major influence on the primary outcome.
We will not correct for the number of centres that re-
cruited patients, although this was a stratification variable.
This because many centres included only a small number
of patients and adjusting for all centres might lead to un-
reliable estimates of the treatment effect. We will perform
a separate sensitivity analysis to evaluate modification of
treatment effect by centre, as described below.
Secondary outcomes
Survival of patients and the proportion of patients with
poor outcome according to the different fixed dichotom-
ous analyses of the mRS (score 4–6 or 3–6), at 3 months
will be expressed as proportions for each treatment
group and the difference will be tested using the chi-
square test and quantified using OR with 95 % CI. ICH
volume will be expressed in absolute mL and the differ-
ence in this volume (i.e. growth) between imaging at
baseline and after 24 hours will be calculated in mL,
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where a positive figure will represent growth and a nega-
tive value will represent shrinkage of ICH. The median
difference in ICH growth will be compared between
treatment groups using the Mann-Whitney U test. The
ordinal distribution of the mRS will be shown for pa-
tients that received platelet transfusion within 3 hours
and between 3 and 6 hours of symptoms separately.
Safety outcomes
Safety outcomes will be reported in the intention-to
treat and as-treated populations. Proportions will be
tested for between-group differences using the chi-
square test and expressed in OR with 95 % CI. For all
continuous variables either means with standard devi-
ation or medians with interquartile range will be calcu-
lated where appropriate and testing for difference will be
performed with either the two-group t test or Mann-
Whitney U test where appropriate.
Subgroup analyses
We will test for modification of the effect of platelet
transfusion on the primary outcome using ordinal re-
gression analyses for the following subgroups:
▪ Pre-ICH antiplatelet therapy used: single vs. dual
therapy
▪ ICH volume at baseline, trichotomised according to
the distribution of ICH volume on the baseline
diagnostic scan
▪ country of randomisation (The Netherlands vs.
Scotland vs. France)
Sensitivity analyses
Using ordinal regression we will test for heterogeneity in
the effect of platelet transfusion on the primary outcome
in the centres that randomised at least five patients
(eight in The Netherlands, three in Scotland, and three
in France), representing 66 % of all patients included. In-
clusion of at least five patients was chosen so that it was
likely that there would be at least one outcome in each
treatment arm of the trial in each centre.
Differences between the protocol and the
statistical analysis plan
The principal difference from the analysis plan specified
in the trial protocol [18] is the analysis of the primary
outcome (mRS) using ordinal logistic regression to cal-
culate the common OR (which was originally specified
as a secondary analysis), rather than a fixed dichotomous
analysis (originally specified as a primary analysis). We
have made this decision for several reasons. First, com-
mon practice in the analysis of ordinal scales like the
mRS as the primary outcome in stroke trials has evolved
to use the ordinal logistic regression approach, because
it is more statistically efficient/powerful, and treatments
for acute stroke (like platelet transfusion) are likely to
shift all patients somewhat on a functional outcome
scale [25]. Second, recent trials have illustrated this
point, by demonstrating a small but clinically meaningful
effect of thrombolysis after acute ischaemic stroke [26]
and intensive blood pressure lowering after ICH [27] on
the mRS by using ordinal logistic regression, but not the
fixed dichotomous approach. Third, the PATCH trial is
particularly likely to benefit from this approach, as a
small trial with a sample size of 190. The power to
detect a common OR of 0.43 (as in the original sample
size calculation) in a shift analysis of all pairs of mRS
categories would increase from 80 % to 91 % with a sam-
ple size of 190 patients. For this calculation we assumed
that the distribution of the mRS in the control arm
would be similar to that in the STICH II trial [28], which
had a similar proportion of patients with poor outcome
as assumed in our original sample size calculation.
Furthermore, there are several differences in the
planned secondary outcomes: ICH volume was calcu-
lated using an automated planimetric method, rather
than the previously described ABC/2 formula. We had
intended to perform a larger sub-study of the spot sign
on CT angiography, but this was performed infrequently
in clinical practice, making this sub-study too small to
generate a statistically meaningful analysis of the modifi-
cation of treatment effect by the spot sign. Similarly, the
platelet function sub-study was only performed in a few
centres in France, precluding any analyses. Funding was
insufficient for the initial planned investigation of causes
of poor outcome, the assessment of functional outcome
using the Amsterdam Medical Centre linear disability
score, and the collection of economic-related data for
the purpose of cost-effectiveness analysis. Description of
the distribution of the mRS in patients that received
platelet transfusion within 3 hours vs. 3 through 6 hours
of symptoms was added, instead of a planned subgroup
analysis according to timing of treatment. This because
timing of treatment was only recorded for those patients
that received platelet transfusion precluding a formal
subgroup analysis.
Lastly, the stratification factor “recruiting centre”
could not be included as a variable to adjust for in the
primary analysis because many centres included a small
number of patients, which could lead to unreliable esti-
mates of the treatment effect. To explore the impact of
this variable on the primary outcome, we opted to per-
form a separate sensitivity analysis at a subset of centres
recruiting five or more patients.
Current trial status
PATCH trial sites recruited from 4 February 2009 in
The Netherlands, from 23 May 2011 in Scotland, and
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from 28 September 2013 in France, and the last patient
was randomised on 8 October 2015. The last follow-up
was obtained on 6 January. At the time of writing, the
trial data have been cleaned and checked for complete-
ness and internal consistency, blinded to treatment allo-
cation. The database will only be locked after this
statistical analysis plan has been date and time stamped
in a public repository.
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J.B. Reitsma (chairman), Department of Clinical Epi-
demiology, Biostatistics and Bioinformatics, Academic
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J.G. van der Bom (chairwoman), Department of Clin-
ical Epidemiology; Leiden University Medical Centre,
Leiden, The Netherlands
A.H. Schreuder, Department of Neurology; Atrium
Medical Centre, Heerlen, The Netherlands
P.W. Kamphuisen, Department of Vascular Medicine;
University Medical Centre Groningen, Groningen, The
Netherlands
I.W. Corten (independent statistician, who prepared
the interim analysis); Clinical Research Unit of the Aca-
demic Medical Centre, The Netherlands.
Safety Committee, France
E. Touzé (chairman), Normandie Université, Univer-
sité de Caen, Inserm U 919, CHU Côte de Nacre,
Caen, France
D. Lasne, Laboratoire d’Hématologie, AP-HP, Hôpital
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A. François, Etablissement Français du Sang, AP-HP,
Hôpital Européen George Pompidou, Paris, France
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